.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BB01_Amantadine.Amantadine_1 .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BB01_Amantadine.Amantadine_1| name: | Amantadine_1 |
| ATC code: | N04BB01_1 | route: | oral |
| n-compartments | 1 |
Amantadine is an antiviral and antiparkinsonian medication that works primarily as an NMDA receptor antagonist and is used to treat Parkinson's disease, drug-induced extrapyramidal symptoms, and formerly for the prophylaxis and treatment of influenza A. The drug is still approved and utilized for Parkinson's disease and related movement disorders.
Pharmacokinetic parameters reported in elderly subjects (mean age 69 years) after single oral dose.
Norkus, C, et al., & KuKanich, B (2015). Pharmacokinetics of oral amantadine in greyhound dogs. Journal of veterinary pharmacology and therapeutics 38(3) 305–308. DOI:10.1111/jvp.12190 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25427541
deVries, T, et al., & Jacobs, D (2019). Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets. CNS drugs 33(8) 783–789. DOI:10.1007/s40263-019-00651-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31342404
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650